Brought to you by 
Eyevensys completes its Series A venture round for total funding of €9mm
03 May 2018
Executive Summary
Eyevensys SA (ocular gene therapy) has raised €1.6mm ($2mm) through its Series A venture round. Innobio (managed by CDC Enterprises), Inserm Transfert Initiative, and CapDecisif Management participated.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Eyevensys completes its Series A venture round for total funding of €9mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice